The Hetero Ring Has At Least Seven Members Patents (Class 514/450)
-
Patent number: 8884032Abstract: Monomeric and dimeric trioxane fluoroaryl amides, 5-carbon-linked, C-10 non-acetal trioxane dimer esters; trioxane silylamides; and trioxane dimer orthoesters and methods of their use for treating subjects infected with malaria or other parasitic infectious diseases including, but not limited to, toxoplasmic infection; subjects afflicted with psychiatric conditions associated with toxoplasmic infection; and subjects afflicted with cancer.Type: GrantFiled: May 19, 2010Date of Patent: November 11, 2014Assignee: The Johns Hopkins UniversityInventors: Gary H. Posner, Lauren E. Woodard, David R. Levine, Deuk Kyu Moon, Bryan T. Mott
-
COMBINATION THERAPY AND USES THEREOF FOR TREATMENT AND PREVENTION OF PARASITIC INFECTION AND DISEASE
Publication number: 20140329894Abstract: The invention relates to compounds, methods, uses, compositions, combinations, kits and packages for the prevention and/or treatment of parasite infection (e.g., Plasmodium parasites) and/or disease (e.g., malaria) based on uses of (a) cystamine, cysteamine, and analogs, derivatives, prodrugs, precursors thereof; an agent capable of inducing their production; and/or salts thereof, and (b) artemisinin and functional derivative, analog, conjugate, metabolite, prodrug or precursor thereof, and/or salts thereof.Type: ApplicationFiled: July 16, 2014Publication date: November 6, 2014Inventors: Philippe Gros, Gundula Min-Oo, Anny Fortin -
Publication number: 20140329893Abstract: Compositions comprising ketone bodies and/or their metabolic precursors are provided that are suitable for administration to humans and animals and which have the properties of, inter alia, (i) increasing cardiac efficiency, particularly efficiency in use of glucose, (ii) for providing energy source, particularly in diabetes and insulin resistant states and (iii) treating disorders caused by damage to brain cells, particularly by retarding or preventing brain damage in memory associated brain areas such as found in Alzheimer's and similar conditions. These compositions may be taken as nutritional aids, for example for athletes, or for the treatment of medical conditions, particularly those associated with poor cardiac efficiency, insulin resistance and neuronal damage. The invention further provides methods of treatment and novel esters and polymers for inclusion in the compositions of the invention.Type: ApplicationFiled: December 3, 2013Publication date: November 6, 2014Applicant: BTG International LimitedInventor: Richard L. Veech
-
Publication number: 20140329771Abstract: The present invention is related to variants of mycolactones of formula (I), processes for the preparation thereof, pharmaceutical compositions thereof and their use in modulating inflammation, immunity and pain. Y—O—W (I), wherein Y and W are as defined in claim 1.Type: ApplicationFiled: November 16, 2012Publication date: November 6, 2014Inventors: Caroline Demangel, Nicolas Blanchard, Georges Bismuth, Jacques Eustache, Virginie Casarotto, Anne-Caroline Chany, Laure Guenin-Mace
-
Patent number: 8877715Abstract: There is provided a series of novel neuropeptide Y-cytotoxic conjugates, compositions comprising the same, and methods relating to their therapeutic use for the treatment of disease or condition states associated with aberrant or undesirable proliferation of cells that express NPY-Y1 receptors.Type: GrantFiled: August 18, 2011Date of Patent: November 4, 2014Assignee: Ipsen Pharma S.A.S.Inventors: Zheng Xin Dong, Kevin Zhou, Daniel B. Deoliveira
-
Publication number: 20140323456Abstract: The present disclosure relates to esters of 8-[2-(2-pentyl-cyclopropylmethyl)cyclopropyl]-octanoic acid (“DCPLA”). The disclosure further relates to compositions, kits, and methods for treatment using the esters.Type: ApplicationFiled: November 13, 2012Publication date: October 30, 2014Inventors: Daniel L. Alkon, Thomas J. Nelson
-
Publication number: 20140323559Abstract: This invention provides for novel antiparasitic and pesticidal forms of moxidectin, including a long-acting polymeric implant. The resulting compounds may be used in veterinary compositions which are used in treating, controlling and preventing of endo- and ectoparasite infections in animals.Type: ApplicationFiled: March 25, 2014Publication date: October 30, 2014Applicant: MERIAL LIMITEDInventors: Susan Mancini Cady, Baoqing Ma, Robert Clark Chapman, Chunhua Yang, Uday Jain
-
Publication number: 20140315842Abstract: The present invention relates to methods of treating a mycobacterial infection. In particular, this invention relates to methods, uses and compounds for use in treating mycobacterial infections, including tuberculosis. For example, the compounds may be an avermectin or a milbemycin. The avermectin or milbemycin may be selected from, but not limited to, one or more of ivermectin, moxidectin or selamectin. Exemplary microbial infections that may be treated include, but are not limited to, infections caused by Mycobacterium tuberculosis, Mycobacterium bovis, other mycobacteria of the tuberculosis complex, and non-tuberculous mycobacteria, including Mycobacterium ulcerans.Type: ApplicationFiled: April 16, 2014Publication date: October 23, 2014Inventors: Charles J. Thompson, Santiago Ramon-Garcia, Leah Elizabeth Lim
-
Publication number: 20140314882Abstract: Combinations of compounds are provided that produce a synergistic effect when administered.Type: ApplicationFiled: June 27, 2014Publication date: October 23, 2014Inventors: Frederick P. ROTH, Murat COKOL, Hon Nian CHUA
-
Publication number: 20140315990Abstract: The present disclosure relates to PKC activators and combinations thereof. The disclosure further relates to compositions, kits, uses, and methods thereof.Type: ApplicationFiled: November 13, 2012Publication date: October 23, 2014Inventors: Daniel L. Alkon, Thomas J. Nelson
-
Patent number: 8865761Abstract: The invention provides novel compounds of Formulas (I)-(IV), as described herein. Also provided are compositions of these compounds, method of making the compounds, and methods of using the compounds. The compounds can be used to regulate cholesterol homeostasis and to treat conditions and diseases associated with cholesterol homeostasis, including lysosomal lipid storage disorders such as Niemann-Pick Disease type C.Type: GrantFiled: August 7, 2013Date of Patent: October 21, 2014Assignee: The University of Notre Dame du LacInventor: Richard Taylor
-
Publication number: 20140303105Abstract: The invention refers to primycin or a primycin component or a combination of primycin components, for use in the treatment or prevention of infections caused by Gram-positive bacteria resistant to methicillin and/or vancomycin and/or mupirocin or by penicillin-resistant streptococci. The invention also covers antibiotic compositions containing these active agents.Type: ApplicationFiled: October 25, 2012Publication date: October 9, 2014Applicant: PANNONPHARMA GYÓGYSZERGYÁRTÓ ZRT.Inventors: Péter Feiszt, Levente Emödy, József Péter Pallos, Ákos Juhász, Dénes Seffer, Mária Sefferné Szalai, Ágota Pénzes
-
Patent number: 8853263Abstract: The present invention is directed to co-therapy for the treatment of epilepsy and related disorders comprising administering to a subject in need thereof, co-therapy with a therapeutically effective amount of a benzo-fused heterocycle sulfamide derivative and a therapeutically effective amount of one or more anticonvulsant and/or anti-epileptic agents.Type: GrantFiled: May 18, 2007Date of Patent: October 7, 2014Assignee: Janssen Pharmaceutica NVInventors: Virginia L. Smith-Swintosky, David F. McComsey, Michael H. Parker, Allen B. Reitz, Bruce E. Maryanoff
-
Publication number: 20140296328Abstract: The present invention is an ophthalmic composition containing a relatively high concentration of olopatadine. The composition is typically an ophthalmic aqueous solution containing relatively high concentrations of olopatadine solubilized within the solution. The composition is preferably capable of providing enhanced relief from symptoms of ocular allergic conjunctivitis, particularly late phase symptoms of ocular allergic conjunctivitis.Type: ApplicationFiled: June 13, 2014Publication date: October 2, 2014Inventors: Daniel A. Gamache, Laman Alani, Malay Ghosh, Francisco Javier Galan, Nuria Carreras Perdiguer, Onkar N. Singh
-
Publication number: 20140296191Abstract: The present invention relates to pharmaceutical compositions of various pharmaceutical actives, especially lyophilic and hydrophilic actives containing Diethylene glycol monoethyl ether or other alkyl derivatives thereof as a primary vehicle and/or to pharmaceutical compositions utilizing Diethylene glycol monoethyl ether or other alkyl derivatives thereof as a primary vehicle or as a solvent system in preparation of such pharmaceutical compositions. The pharmaceutical compositions of the present invention are safe, non-toxic, exhibits enhanced physical stability compared to conventional formulations containing such pharmaceutical actives and are suitable for use as injectables for intravenous and intramuscular administration, as well as for use as a preformed solution/liquid for filling in and preparation of capsules, tablets, nasal sprays, gargles, dermal applications, gels, topicals, liquid oral dosage forms and other dosage forms.Type: ApplicationFiled: April 2, 2014Publication date: October 2, 2014Applicant: THEMIS MEDICARE LIMITEDInventors: Dinesh Shantilal PATEL, Sachin Dinesh PATEL, Shashikant Prabhudas KURANI, Madhavlal Govindlal PATEL
-
Patent number: 8846750Abstract: The present invention relates to pharmaceutical and food compositions for preventing or treating diabetes or obesity, and more particularly to pharmaceutical compositions and functional foods for preventing or treating diabetes or obesity, which contain, as an active ingredient, a novel compound synthesized from a compound separated from an extract of the Stereocaulon alpinum. The novel compounds of the invention have very excellent PTP-1b (protein tyrosine phosphatase-1b) inhibitory activities, act selectively only on PTP-1b among protein tyrosine phosphatases, and are substantial PTP-1b inhibitors which are effective in preventing or treating diabetes or obesity.Type: GrantFiled: July 1, 2011Date of Patent: September 30, 2014Assignee: Korea Ocean Research and Development InstituteInventors: Joung Han Yim, Il Chan Kim, Doc Kyu Kim, Se Jong Han, Hyoung Seok Lee, Bhattarai Hari Datta, Jung Eun Kim, Tai Kyoung Kim, Hyun Cheol Oh, Dong-Gyu Jo, Cheolsoon Lee, Keun-Sik Kim, Pyung Cheon Lee, Mi Ra Park, Yu-Kyung Park, Sung Jin Kim, Pil-Sung Kang, Heeyong Park, Ha Ju Park
-
Patent number: 8841341Abstract: The invention provides a compound termed Carolacton having the structure and derivatives thereof for medical use against biofilm formation by bacteria.Type: GrantFiled: September 5, 2008Date of Patent: September 23, 2014Assignee: Helmholtz-Zentrum fuer Infektionsforschung GmbHInventors: Brigitte Kunze, Irene Wagner-Döbler, Herbert Irschik, Heinrich Steinmetz, Dietmar Schummer
-
Publication number: 20140275171Abstract: The invention relates to macrocyclic picolinamides of Formula I and their use as fungicides.Type: ApplicationFiled: May 28, 2014Publication date: September 18, 2014Inventors: Kevin G. Meyer, JR., Karla Bravo-Altamirano, James M. Renga, Jessica Herrick, Benjamin Nugent, Timothy Boebel, Fangzheng Li, Nick X. Wang, W. John Owen, Paul Graupner, Chenglin Yao, Ronald J. Heemstra
-
Publication number: 20140275010Abstract: The present invention provides quaternary salts, such as those of Formula I: as well as the use thereof in methods of treatment for cancer.Type: ApplicationFiled: March 11, 2014Publication date: September 18, 2014Inventors: Guo Zhu Zheng, Yuan Wang, Gregg F. Keany, Kenzo Arai, Kazunobu Kira, Xiang Liu, Nick Gearhart, Baudouin Gerard
-
Patent number: 8835462Abstract: The disclosure relates to macrocyclic picolinamides of Formula I and their use as fungicides.Type: GrantFiled: May 6, 2013Date of Patent: September 16, 2014Assignee: Dow AgroSciences, LLC.Inventors: Kevin G. Meyer, W. John Owen, James M. Renga, Chenglin Yao, Benjamin M. Nugent, Jeremy Wilmot, Fangzheng Li, Karla Bravo-Altamirano
-
Publication number: 20140256619Abstract: The present invention relates to the use of avermectin derivative as a drug for the treatment of parasitic infections. The avermectin derivative is represented by the formula (I) wherein: (i) R1 is chosen from the group constituted of —CH(CH3)2, —CH(CH3)CH2CH3, or cyclohexyle, (ii) X represents —CH2CH2—, or —CH?CH—, (iii) R2 is chosen from the group constituted of or —OH group, (iv) R3 is OH or NOH, (v) represents a single bond when R3 is OH, or a double bond when R3 is NOH, as an inhibitor of a membrane-bound protein which transports exogenous compounds out of target cells.Type: ApplicationFiled: October 18, 2012Publication date: September 11, 2014Inventors: Anne Lespine, Roger Prichard, Cecile Menez
-
Patent number: 8822528Abstract: This invention relates to novel polyether ionophores, formulations comprising same, and to methods of making and using these compounds and formulations for the treatment and/or prevention of parasitic infection in animals and humans. These compounds exhibit improved safety profiles and/or efficacies as compared to parent compounds.Type: GrantFiled: November 16, 2011Date of Patent: September 2, 2014Assignees: Merial Limited, Universite Claude Bernard Lyon 1, Centre National de la Recherche Scientifique (CNRS)Inventors: Jean Delaveau, Emile Vialle, Marc Lemaire, Stephane Pellet-Rostaing, Bruno Andrioletti
-
Publication number: 20140243402Abstract: The invention relates to the treatment of kintoplastid infections by administering a pharmaceutical composition containing an extract from the plant Artemisia annua. The invention also relates to isolated, semi-synthetic and synthetic artemisinins that show improved efficacy in treating kinetoplastid infections. This invention also relates to a method of treating kintoplastid infections with artelinic acid and artemisinins and where Artelinic acid is administered orally.Type: ApplicationFiled: February 4, 2014Publication date: August 28, 2014Applicant: The United States of America as represented by the Secretary of the ArmyInventors: Bruno K. Kubata, Samuel K. Martin, Wilbur K. Milhous
-
Publication number: 20140242138Abstract: Method for the preparation of microencapsulated essential oils or a formulation thereof for various non-agricultural applications.Type: ApplicationFiled: May 7, 2014Publication date: August 28, 2014Applicant: BOTANOCAP LTD.Inventors: Amnon Kritzman, Arie Markus, Pnina Strongin, Charles Linder
-
Publication number: 20140242199Abstract: Compositions useful for controlling pests are disclosed. In some embodiments, the composition includes a pesticidal natural oil and a polar aromatic solvent. Methods of making and using the compositions are disclosed.Type: ApplicationFiled: October 4, 2012Publication date: August 28, 2014Inventors: Karan Manhas, Annett Rozek
-
Publication number: 20140243403Abstract: The invention relates to methods of determining an appropriate chemotherapy for a subject based on expression levels of a TAK1 biomarker, such as one or more TAK1 biomarkers listed in Table 1, or any subset or combination thereof, e.g., a set of biomarkers consisting of or comprising GGH, BMP7, BAMBI, MBOAT2, HSPA12A, FYN, NAV2, RGL1, SYK and RUNX1 genes, optionally with one or both of INHBB and/or BMPR1A. In some embodiments, the biomarkers include one, two, three, or all of BMP7, BAMBI, BMPR1A, and INHBB. Kits useful for the methods are also provided.Type: ApplicationFiled: May 29, 2012Publication date: August 28, 2014Applicant: The General Hospital CorporationInventors: Anurag Singh, Daniel A. Haber, Jeffrey E. Settleman
-
Publication number: 20140243284Abstract: The present invention provides a compound of the formula (I) or (II), wherein R1 is H, alkyl, alkenyl or aryl, R2 is H, alkyl or aryl, R3 is H, a alkyl, alkenyl or aryl, R4 and R4-R8 are independently R10, C(O)R10 or SO2R10, wherein R10 is H, alkyl, alkenyl or aryl, and R9 is R9a, C(O)R9a or SO2R9a, wherein R9a is H, alkyl, alkenyl or aryl. R9a can be unsubstituted or substituted with one or more oxo(?O), OR9b, OC(O)R9b, OSO2R9b, NHR9b, NHC(O)R9b and NHSO2R9b groups. R9b is H, alkyl, alkenyl, or aryl. R9b can be unsubstituted or substituted with one or more groups such as oxo(?O), OR9c, CO2R9c, CO2R9c and OC(O)R9c. R9c is H, or a unsubstituted or substituted alkyl, alkenyl or aryl. The present invention further provides a composition comprising at least one compound of the present invention and a pharmaceutically acceptable carrier, alone or in combination with at least one additional active agent.Type: ApplicationFiled: May 12, 2014Publication date: August 28, 2014Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Michael R. Boyd, Kirk R. Gustafson, Charles L. Cantrell
-
Publication number: 20140242030Abstract: Provided is a novel anti-HCV agent including as an active ingredient a peroxide derivative represented by the general formula (I). In the general formula (I), C represents an alicyclic hydrocarbon ring group which may be substituted, n represents an integer of from 1 to 6, and R represents a hydrogen atom or a hydroxyalkyl group. The peroxide derivative exhibits potent anti-HCV activity by remarkably suppressing HCV-RNA replication.Type: ApplicationFiled: October 2, 2012Publication date: August 28, 2014Applicant: National University Corporation Okayama UniversityInventors: Nobuyuki Kato, Masanori Ikeda, Yusuke Wataya, Hye-Sook Kim, Hiroyuki Doi
-
Patent number: 8815938Abstract: Double compartment skincare products confine a first compartment containing an anhydrous composition including an active ingredient, and a second compartment, wherein the active ingredient is selected from among compounds of the avermectin family and compounds of the milbemycin family, and are useful as medicaments for the treatment and/or prevention of dermatological conditions/afflictions.Type: GrantFiled: April 10, 2009Date of Patent: August 26, 2014Assignee: Galderma S.A.Inventors: Sandrine Segura-Orsoni, Fabienne Louis
-
Patent number: 8815844Abstract: The present invention relates to the compounds useful in the prevention and/or treatment of tumors. More specifically the present invention relates to inhibitors of the activity of the electron transport chains and/or the mitochondrial TCA cycle in glioma-initiating cells (GICs) for use in a method for preventing and/or treating tumors presenting glioma-initiating cells (GICs) in a subject who has undergone a prior removal of a tumor glioma bulk. The present invention further provides a pharmaceutical composition containing the inhibitors of the invention and a screening method for identifying the inhibitors of the invention.Type: GrantFiled: May 20, 2010Date of Patent: August 26, 2014Assignees: Universite de Geneve, Hopitaux Universitaires de GeneveInventors: Virginie Clement, Ivan Radovanovic
-
Publication number: 20140227326Abstract: A method of delivering a nasal spray. A sprayer having a formulation comprising olopatadine is provided. A spray of the formulation is delivered to a subject's nose. The spray may have a spray characteristic comprising a spray pattern having a longest axis of 20-45 mm, a shortest axis of 14-20 mm, and an ellipticity of 1-1.8. The spray may also have a spray characteristic comprising a droplet size distribution having a D10 of 15-30 ?m, a D50 of 30-60 ?m, a D90 of 50-150 ?m, a SPAN of not more than 3, and a % Volume of <10 ?m of less than 4%.Type: ApplicationFiled: November 14, 2013Publication date: August 14, 2014Applicant: Novartis AGInventors: Gerald D. Cagle, G. Michael Wall
-
Patent number: 8802125Abstract: The invention concerns a system for biocompatible drug release comprising: (i) a polymer matrix; (ii) an inorganic component located inside said matrix and characterized by a lamellar structure with a net positive or negative charge able to intercalate (iii) a pharmacologically active principle into said lamellar structure, by establishing an ionic type of bond with it and thereby obtaining an intercalation compound. The preparation process for the release system comprises the stages of: treating the lamellar solid in such a way as to give it a net positive or negative charge, then combining it with the chosen active principle, also in an ionic form, to obtain an intercalation compound which is then mixed with the polymer matrix. The release system can be employed in making medical devices, like sutures, membranes, osteosynthesis plaques, multilayered devices, gels and drug delivery systems.Type: GrantFiled: July 21, 2006Date of Patent: August 12, 2014Assignee: ARIANNA Medical DevicesInventors: Gaetano Marenzi, Adele Bolognese, Luigi Califano, Antonio Calignano, Umberto Costantino, Gilberto Sammartino, Vittoria Vittoria
-
Publication number: 20140221468Abstract: Store operated calcium channel modulating compounds, and methods for using the same, are provided. These compounds and methods find use in a variety of applications in which modulation of store operated calcium channels is desired.Type: ApplicationFiled: December 9, 2011Publication date: August 7, 2014Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Chan Young Park, Amir M. Sadaghiani, Ricardo Ei Dolmetsch
-
Publication number: 20140213618Abstract: The present invention provides compounds of formula (I): as described generally and in classes and subclasses herein. The present invention additionally provides pharmaceutical compositions comprising compounds of formula (I) and provides methods of treating cancer comprising administering a compound of formula (I).Type: ApplicationFiled: August 20, 2013Publication date: July 31, 2014Inventors: Samuel J. Danishefsky, Alexey Rivkin, Yoshimura Fumihiko, Ting-Chao Chou, Ana E. Gabarda, Huajin Dong
-
Publication number: 20140213642Abstract: Disclosed is a novel C-aryl ansa compound having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes. Also provided are a method for preparing the compound, and a method for preventing or treating metabolic disorders, particularly diabetes, by using the compound.Type: ApplicationFiled: June 14, 2012Publication date: July 31, 2014Applicant: GREEN CROSS CORPORATIONInventors: Min Ju Kim, Suk Ho Lee, Soongyu Choi
-
Patent number: 8791153Abstract: An avermectin-based topical formulation is disclosed which is useful for prevention and treatment of head lice (Pediculus humanus capitis). This topical formulation may be formulated as a shampoo-condition which comprises an effective amount of avermectin, solubilizers, suspending agents, preservatives, non-ionic surfactants, humectants, a silicone compound, and water. Also disclosed are methods of using the topical formulations disclosed within this specification to treat either a susceptible or treatment-resistant strain of lice, as well as uses in the manufacture of a medicament for treating or preventing a lice infestation from a susceptible or treatment-resistant strain in a human patient.Type: GrantFiled: October 12, 2007Date of Patent: July 29, 2014Assignee: Sanofi-Topaz, Inc.Inventors: Nicholas Spring, Garry T Gwozdz
-
Patent number: 8791154Abstract: The present invention is an ophthalmic composition containing a relatively high concentration of olopatadine. The composition is typically an ophthalmic aqueous solution containing relatively high concentrations of olopatadine solubilized within the solution. The composition is preferably capable of providing enhanced relief from symptoms of ocular allergic conjunctivitis, particularly late phase symptoms of ocular allergic conjunctivitis.Type: GrantFiled: May 18, 2012Date of Patent: July 29, 2014Assignee: Alcon Research, Ltd.Inventors: Daniel A. Gamache, Laman Alani, Malay Ghosh, Francisco Javier Galán, Núria Carreras Perdiguer, Onkar N. Singh
-
Publication number: 20140206760Abstract: The invention relates to compounds of the formula (I) which are inhibitors of activated thrombin-activable fibrinolysis inhibitor. The compounds of the formula I are suitable for producing medicaments for prophylaxis, secondary prevention and treatment of one or more disorders associated with thromboses, embolisms, hypercoaguability or fibrotic changes.Type: ApplicationFiled: March 26, 2014Publication date: July 24, 2014Applicant: SANOFIInventors: Christopher Kallus, Mark Broenstrup, Andreas Evers, Anja Globisch, Herman Schreuder, Michael Wagner
-
Patent number: 8785479Abstract: The invention relates to macrocyclic picolinamides of Formula I and their use as fungicides.Type: GrantFiled: May 6, 2013Date of Patent: July 22, 2014Assignee: Dow AgroSciences, LLC.Inventors: Kevin G. Meyer, Karla Bravo-Altamirano, James M. Renga, Jessica Herrick, Benjamin M. Nugent, Timothy A. Boebel, Fangzheng Li, Nick X. Wang, W. John Owen, Paul R. Graupner, Chenglin Yao, Ronald J. Heemstra
-
Patent number: 8785483Abstract: Embodiments of the invention include methods and compositions involving aldose reductase inhibitors for treating COPD.Type: GrantFiled: December 23, 2011Date of Patent: July 22, 2014Assignee: The Board of Regents of the University of Texas SystemInventors: Satish K. Srivastava, Kota V. Ramana, Umesh Yadav
-
Publication number: 20140199296Abstract: A pharmaceutical composition comprising a cancer therapeutic that is capable of inhibiting and/or reducing the ability of a cancer cell to take up and utilize glucose or other energy source, a lipid or other building block of a cell membrane or organelle, and/or cholesterol. The pharmaceutical composition can comprise one or more cancer therapeutics that can be administered individually or in combination to an individual.Type: ApplicationFiled: January 14, 2014Publication date: July 17, 2014Applicant: BIOCOPEA LIMITEDInventors: Robin M. Bannister, John Brew, Gregory A. Stoloff
-
Publication number: 20140194495Abstract: The present invention concerns groups of compounds derived from tunicates of the Synoicum species, as well as to pharmaceutical compositions comprising these compounds, and uses thereof. Extracts from tunicates show selective toxicity against several different cancer cell lines in the NCI 60 cell line panel. These compounds are useful in the effective treatment of cancers, particularly malignant melanomas, colon cancer, and renal cancer cell lines.Type: ApplicationFiled: March 11, 2014Publication date: July 10, 2014Applicants: THE UAB RESEARCH FOUNDATION, UNIVERSITY OF SOUTH FLORIDAInventors: BILL J. BAKER, THUSHARA DIYABALANAGE, JAMES B. MCCLINTOCK, CHARLES D. AMSLER
-
Publication number: 20140194496Abstract: Methods and compositions for inhibiting integrin and treating integrin-related conditions, utilizing tellurium-containing compounds, are disclosed. The tellurium-containing compounds comprise at least one tellurium dioxo moiety and may have any one of Formulae I to IV as defined in the specification. Further disclosed are methods and compositions for treating a neoplastic condition characterized by a resistance to an anti-neoplastic agent and by a high level of expression of an integrin by neoplastic cells.Type: ApplicationFiled: March 13, 2014Publication date: July 10, 2014Applicant: BIOMAS LTD.Inventors: Benjamin SREDNI, Michael ALBECK
-
Publication number: 20140187557Abstract: The present invention relates to a compound of formula (I) including any stereochemically isomeric form thereof, wherein the substituents are as defined in the specification and the claims; a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof; provided that the compound is other than or a pharmaceutically acceptable salt thereof. The claimed compounds are useful for the treatment of a disease, the treatment of which is affected, mediated or facilitated by activating the GHS1A-r receptor. The invention also relates to pharmaceutical compositions thereof and processes for the preparation thereof.Type: ApplicationFiled: March 10, 2014Publication date: July 3, 2014Applicant: Janssen Pharmaceutica NVInventors: Bruno Schoentjes, Alain Philippe Poncelet, Julien Georges Pierre-Olivier Doyon, Joannes Theodorus Maria Linders, Lieven Meerpoel, Luc August Laurentius Ver Donck
-
Publication number: 20140187619Abstract: Methods of treatment in subjects suffering from diabetes mellitus or obesity are provided. The methods comprise the step of administering an active agent directly to the small intestine in the subject. In particular, the active agent may be administered directly to the duodenum in the subject. The active agents useful in the treatments described herein include analgesic agents and, in particular, antinociceptive agents such as capsaicin, resiniferatoxin, and their analogues.Type: ApplicationFiled: July 18, 2012Publication date: July 3, 2014Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Pankaj Jay Pasricha, Liansheng Liu
-
Publication number: 20140186367Abstract: Embodiments of the invention are directed to methods of determining the prognosis of a breast cancer patient by evaluating the activity of the glucocorticoid receptor in tumor cells. Other embodiment include methods of treating breast cancer cells, particularly, chemo-resistant cells, with a glucocorticoid receptor antagonist and an anticancer agent or compound.Type: ApplicationFiled: February 4, 2014Publication date: July 3, 2014Applicant: The University of ChicagoInventors: Deng PAN, Masha Kocherginsky, Suzanne D. Conzen
-
Publication number: 20140187588Abstract: The disclosure relates to macrocyclic picolinamides of Formula (I) and to the use of these compounds as fungicides.Type: ApplicationFiled: December 27, 2013Publication date: July 3, 2014Inventors: Rebecca Lalonde, Kevin G. Meyer, Fangzheng Li, Jeremy Wilmot, Karla Bravo-Altamirano, Chenglin Yao, Iain O'Callaghan, Jessica Herrick, Kyle DeKorver, Yu Lu
-
Publication number: 20140187618Abstract: Compositions, methods, and kits including extracts containing physalins and pure physalins are provided for inducing neurogenesis in cells and tissues. The extracts for example are obtained from natural sources such as a plant, for example Physalis angulata. The extracts and purified physalins increase proliferation of neural stem cells, differentiation of the neural progenitor cells in areas of the brain, for example the hippocampus, and are effective for treating neurodegenerative disorders, neurological disease, and neurological conditions.Type: ApplicationFiled: December 31, 2013Publication date: July 3, 2014Applicant: Biocrescentia, LLCInventors: Milton Nascimento da Silva, Alberto Cardoso Arruda, Mara Silvia Pinheiro Arruda, Gilmara de Nazareth Tavares Bastos, Raquel Carvalho Montenegro, José Luiz Martins do Nascimento
-
Patent number: 8765160Abstract: A method for the control of soil-dwelling pests and/or soil-borne diseases comprising treating a plant propagation material with an effective amount of the pesticidal composition and/or applying an effective amount of a pesticidal composition to a locus where control is desired, provided that the composition comprises, as active ingredient, one or more pesticides (A) having a water solubility of at most 100 ?g/liter, at 25° C. at neutral pH, and at least one formulation auxiliary, wherein the size of particles in the composition is in the range 3.60 ?m to 0.70 ?m at X90. Abamectin has been found to be particularly effective against nematode damage.Type: GrantFiled: September 18, 2006Date of Patent: July 1, 2014Assignee: Syngenta Crop Protection LLCInventors: Frederique Guyon, Christoph Grimm
-
Publication number: 20140179772Abstract: The invention provides pharmaceutical compositions for the treatment and prophylaxis of malaria, comprising artemether and a medium chain triglyceride formulated for transmucosal sublingual, buccal or nasal delivery, especially by a spray. Also provided are delivery devices containing the compositions.Type: ApplicationFiled: July 26, 2013Publication date: June 26, 2014Applicant: Protopharma LimitedInventors: Clive Booles, Calvin Ross, Martin Sams